Chembio takes rapid HIV tests to the US
This article was originally published in Clinica
Executive Summary
Paving its entry into the lucrative US HIV testing market, Chembio Diagnostics has gained FDA approval for its rapid HIV tests. Clearance of its Sure Check HIV 1/2 and HIV 1/2 Stat-Pak tests will allow the company to tap into a US rapid HIV test professional market that it believes will exceed $50m within the next couple of years. Chembio is currently in discussions with a partner to market the products in the US.
You may also be interested in...
Sandoz Pioneers Posaconazole And Silodosin In Canada
Sandoz Canada has become the first manufacturer to launch generic versions of posaconazole and silodosin in Canada. The company launched the generic version of Allergan’s Rapaflo (silodosin) after a Canadian court ruled that Sandoz did not infringe a key formulation patent.
Amarin Pulls Insurer Into Hikma/Vascepa Induced Infringement Suit
US healthcare insurance provider Health Net failed to respect Amarin’s patent rights in the way it distributed Hikma’s generic version of Vascepa (icosapent ethyl), the originator contends in an expanded induced infringement suit.
Dutch Supplements Firm Caught Buying Fake Instagram Followers
Netherlands' Authority for Consumers and Markets has reprimanded a dietary supplements player for purchasing fake followers and likes on social media to exaggerate the popularity of its products. It is the first case of its kind in the country.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: